Research at NDDRL focuses on the development of nanobased drug delivery systems that potentially enhance the therapeutic activity and minimize undesired effects of the tailored drug. NDDRL exploits the knowledge gained from research on the basis of experimental evidences for the next generation targeted therapies of life-threatening diseases. Our mission is to serve humanity by developing potential nanomedicines for treatment of life-threatening diseases with special attention towards asthma & related disorders, hepatocellular carcinoma, Skin & Ocular infections and brain disorders. We are currently pursuing the following research projects:

1. Development of Nano Dry powders for Asthma Therapy

Development of nanotechnology based respiratory powders with better aerosolization effects is an open challenge for formulation scientists. Here we accepted the task and formulating nanoparticles by using various precipitation technique and also studying effect of drying methods on particle performance in lungs. Ultra HPLC-ESI-qTOF-MS will estimate the drugs in lungs and bronchio-alveolar lavage.

2. Nanoconjugates for the efficient delivery of botanicalsin hepatoprotection

We emphasize a fundamental understanding of how herbal nanoconjugates play a lead role inhepatoprotection. We utilize nanocojugation platform to develop a robust formulation that can deliver valuable hepatoprotective agents to the liver cells. Nanotoxicological evaluation will determine the safety and quality of the optimised formulation.

3. Nanotechnology based Chemopreventive approaches to improve delivery of Anticancer agents

Hepatocellular carcinoma is the sixth most common cancer and the third leading cause of cancer mortality in the world. Many pharmaceutical agents have been discovered by screening natural products from plants, and some of them are under clinical practices including vincristine, vinblastine, irinotecan, etoposideand paclitaxel. These herbal drugs are being employed in cancer treatment, due to their lead performance and safe status.However, many anti-cancer agents cannot be administered orally due to their low aqueous solubility, degradation by digestive intestinal enzymes, poor permeability across the intestinal epithelium, extensive elimination by first pass metabolism, or poor permeability across the small intestinal epithelium. Our research focuses on identifying novel methods in order to improve the oral delivery of anticancer nanoparticles into the core of hepatictumours to show promising activity.

4. Development of "Lipid" Nanoparticles for Skin Delivery of Botanicals

Recent advances in herbal drug development have led to the advancement of several delivery aspects of botanicals including nanoemulsion, liposomes, phytosomes, niosomes, and polymeric nanobiomaterials. One of the key challenges hampering the development of these herbal drugs into clinically-effective therapies is their little orientation over existed active pharmaceuticals. NDDRL focuses on the rational design and delivery of isolated phytoconstituentsas functional “Lipid” nanopharmaceuticals that can respond to severity of inflammatory skin conditions (e.g.Arthritis, Acne vulgaris, Onchomycosis). We utilize in house techniques to nanosize these "natural bioactives" to improve delivery aspects.


5. Engineering Nano-Ocular Drug Delivery Systems

Controlled Ocular drug delivery is one of the most challenging fields of pharmaceutical research at global scale. Low drug-contact time and poor ocular bio-availability due to drainage of solution, tear turnover and lacrimation rate are the problems generally encountered with conventional systems. Nanoscale technology is a promising drug delivery system that could be employed to improve the pharmacokinetic properties of clearance and distribution in ocular drug delivery to the retina. Our goal is to optimise nanoformulations that can deliver incorporated drug in a controlled fashion in the severity of eye infections.

Copyright © 2014 NDDRL